Loading patent…
AssigneeHuxley Health Inc.
InventorsJohn Trant, Abd Al-Aziz A. Abu-Saleh, Muhammad Usman Mirza
Estimating the term…
Disclosed are a variety of phenethylamine-based 5-HT2AR agonists that, in silico, show higher predicted affinity than phenethylamine. The agonists of the present disclosure are expected to demonstrate therapeutic benefits in treating mental disorders. In some embodiments, the invention may comprise the use of the compounds of the present invention to treat depression, and particularly drug-resistant depression. Other conditions that may be treated include: anxiety disorders, including anxiety in advanced stage illness e.g. cancer as well as generalized anxiety disorder, depression including major depressive disorder, postpartum depression, cluster headaches, obsessive-compulsive disorder, personality disorders, including conduct disorder, drug disorders including: alcohol dependence, nicotine dependence, opioid dependence, cocaine dependence and other addictions including gambling disorder, eating disorder and body dysmorphic disorder, chronic pain, or chronic fatigue.
A therapeutically effective composition comprising an active ingredient that comprises an active ingredient having a chemical structure selected from at least one of the following:
A therapeutic treatment process that comprises administering to a human or mammal subject in need thereof a therapeutically-effective amount of:
A method for the treatment of depression, comprising administering an effective amount of a composition comprising a selective 5-HT2AR inverse agonist to a human in need of such treatment, wherein said composition comprises an active ingredient that comprises TTA068, TTA070, TTA071, TTA072, TTA074, TTA076, TTA080, TTA083, TTA085, TTA091, or TTA094, their pharmaceutically acceptable salts, or diastereomers thereof.
Dependencies are inferred from the claim text.